Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560021 | 1.00 | KMT2A (0.49) | KMT2AMEN1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL10088120 | 1.00 | KMT2A (0.49) | KMT2AMEN1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL559737 | 1.00 | KMT2A (0.49) | KMT2AMEN1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL560223 | 1.00 | KMT2A (0.49) | KMT2AMEN1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL560022 | 1.00 | KMT2A (0.49) | KMT2AMEN1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL10088118 | 1.00 | KMT2A (0.49) | KMT2AMEN1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL13844616 | 1.00 | KMT2A (0.49) | KMT2AMEN1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL12169853 | 1.00 | KMT2A (0.49) | KMT2AMEN1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL560222 | 1.00 | KMT2A (0.49) | KMT2AMEN1MAPTKDM4ESMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL560400 | 0.99 | KMT2A (0.48) | KMT2AMEN1MAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048647-B2 | Aldolase, and method for producing optically active IHOG and monatin | AJINOMOTO CO., INC. (JP) | 2011-11-01 | — | — | US | claimed |
| US-20100184165-A1 | NOVEL ALDOLASE, AND METHOD FOR PRODUCING OPTICALLY ACTIVE IHOG AND MONATIN | AJINOMOTO CO., INC. (JP) | 2010-07-22 | — | — | US | claimed |
| US-7662596-B2 | Aldolase, and method for producing optically active IHOG and monatin | AJINOMOTO CO., INC. (JP) | 2010-02-16 | — | — | US | claimed |
| US-20090258403-A1 | NOVEL ALDOLASE, AND METHOD FOR PRODUCING OPTICALLY ACTIVE IHOG AND MONATIN | AJINOMOTO CO., INC. (JP) | 2009-10-15 | — | — | US | claimed |
| US-7354746-B1 | Method for producing optically active IHOG and monatin | AJINOMOTO CO., INC. (JP) | 2008-04-08 | — | — | US | claimed |
| US-7241599-B2 | Aldolase, and method for producing optically active IHOG and monatin | AJINOMOTO CO., INC. (JP) | 2007-07-10 | — | — | US | claimed |
| US-20060003426-A1 | Novel aldolase, and method for producing optically active IHOG and monatin | AJINOMOTO CO., INC. (JP) | 2006-01-05 | — | — | US | claimed |
| EP-1605041-A2 | Aldolase, and method for producing optically active IHOG and monatin | Ajinomoto Co., Inc. (JP) | 2005-12-14 | — | — | EP | claimed |
| US-20050244939-A1 | Variant aldolase and processes for producing an optically active IHOG and an optically active monatin using the same | AJINOMOTO CO., INC. (JP) | 2005-11-03 | — | — | US | claimed |
| EP-1806408-B1 | Process for producing amino acid derivatives from hydroxyimino acids | AJINOMOTO KK (JP) | 2012-04-18 | — | — | EP | disclosed |
| EP-1719758-B1 | PROCESS FOR PRODUCING MONATIN | AJINOMOTO KK (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120035373-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC (JP) | 2012-02-09 | — | — | US | disclosed |
| US-8048647-B2 | Aldolase, and method for producing optically active IHOG and monatin | AJINOMOTO CO., INC. (JP) | 2011-11-01 | — | — | US | disclosed |
| US-8043836-B2 | Contacting Citrobacter/Escherichia and/or enzyme with a hydroxyimino acid; for biosynthesis of tryptophan | AJINOMOTO CO., INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20060074249-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO. INC (JP) | 2006-04-06 | — | — | US | disclosed |
| US-20060003426-A1 | Novel aldolase, and method for producing optically active IHOG and monatin | AJINOMOTO CO., INC. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1605041-A2 | Aldolase, and method for producing optically active IHOG and monatin | Ajinomoto Co., Inc. (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20050244939-A1 | Variant aldolase and processes for producing an optically active IHOG and an optically active monatin using the same | AJINOMOTO CO., INC. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004394-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO. IN (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1466890-A1 | PROCESSES FOR THE PREPARATION OF GLUTAMIC ACID COMPOUNDS AND INTERMEDIATES THEREOF AND NOVEL INTERMEDIATES USED IN THE PROCESSES | Ajinomoto Co., Inc. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035373-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885 |
| US-20050004394-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | GLUL, MON2, GRIK5 | KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885 |
| US-20050244939-A1 | Variant aldolase and processes for producing an optically active IHOG and an optically active monatin using the same | ALDOA, MON2, HOGA1 | KMT2A 1076/4885MEN1 102/4885MAPT 817/4885 |
| US-20060074249-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | GLUL, MON2, GRIK5 | KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.